Mylan’s $1.6 Billion Strides Deal Delayed, Newspaper Says

Mylan Inc.’s $1.6 billion acquisition of a Strides Arcolab Ltd. unit has been put on hold as Indian regulators raise concern about foreign ownership of companies that make cancer drugs, the Economic Times reported.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.